226 related articles for article (PubMed ID: 16750490)
1. Keynote comment: Cancer drug pricing in the USA.
Johnson DH
Lancet Oncol; 2006 Jun; 7(6):444-5. PubMed ID: 16750490
[No Abstract] [Full Text] [Related]
2. United healthcare, five oncology practices try bundled payments.
Goozner M
J Natl Cancer Inst; 2011 Jan; 103(1):8-10. PubMed ID: 21169535
[No Abstract] [Full Text] [Related]
3. Ethics of cost containment for cancer therapies: will the Affordable Care Act bring down costs?
Caplan A
Oncology (Williston Park); 2012 Dec; 26(12):1227-9. PubMed ID: 23413608
[No Abstract] [Full Text] [Related]
4. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
5. The rising cost of pharmaceuticals: a physician's perspective.
Shulkin DJ
Am J Hosp Pharm; 1993 Aug; 50(8 Suppl 4):S8-10. PubMed ID: 8213863
[No Abstract] [Full Text] [Related]
6. Strategies to reduce cancer-care costs.
Goozner M
J Natl Cancer Inst; 2013 Feb; 105(4):247-8. PubMed ID: 23369949
[No Abstract] [Full Text] [Related]
7. Electronic medical records: oncology practices take the plunge.
Hede K
J Natl Cancer Inst; 2009 Jul; 101(14):976-83. PubMed ID: 19584325
[No Abstract] [Full Text] [Related]
8. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.
American Society of Clinical Oncology
J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877
[No Abstract] [Full Text] [Related]
9. Targeted immunotherapies overtaking emerging oncology market value based growth.
Jakovljevic MB
J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
[No Abstract] [Full Text] [Related]
10. The tipping point: it's time for oncologists to prepare for change.
Zweigenhaft B
Oncology (Williston Park); 2010 Nov; 24(13):1195-6. PubMed ID: 21192558
[No Abstract] [Full Text] [Related]
11. [Increase in incidence of drug treatments, ethical principles and conflict of interest in cooperation with the pharmaceutical industry].
Hebebrand J; Blanz B; Herpertz-Dahlmann B; Lehmkuhl G
Z Kinder Jugendpsychiatr Psychother; 2012 May; 40(3):133-8. PubMed ID: 22774235
[No Abstract] [Full Text] [Related]
12. ASCO supports government report: "Off-label drugs: reimbursement policies constrain physicians in choice of cancer therapies".
Oncology (Williston Park); 1991 Oct; 5(10):29-30, 33. PubMed ID: 1838269
[No Abstract] [Full Text] [Related]
13. What is the impact of free drug samples on patients?
Downey LV
South Med J; 2008 Sep; 101(9):879-80. PubMed ID: 18708974
[No Abstract] [Full Text] [Related]
14. Does reimbursement influence chemotherapy treatment for cancer patients?
Jacobson M; O'Malley AJ; Earle CC; Pakes J; Gaccione P; Newhouse JP
Health Aff (Millwood); 2006; 25(2):437-43. PubMed ID: 16522584
[TBL] [Abstract][Full Text] [Related]
15. Increase in oral cancer drugs raises thorny issues for oncology practices.
Hede K
J Natl Cancer Inst; 2009 Nov; 101(22):1534-6. PubMed ID: 19880814
[No Abstract] [Full Text] [Related]
16. Reforming the payment system for medical oncology.
Bach PB
JAMA; 2013 Jul; 310(3):261-2. PubMed ID: 23817729
[No Abstract] [Full Text] [Related]
17. Opioid consumption in Italy: industry is not necessarily business--look at the effects.
Mercadante S
J Pain Symptom Manage; 2004 May; 27(5):391-2. PubMed ID: 15120764
[No Abstract] [Full Text] [Related]
18. Rethinking prescribing in the United States.
Ellner A
BMJ; 2003 Dec; 327(7428):1397-400. PubMed ID: 14670892
[TBL] [Abstract][Full Text] [Related]
19. The reawakening of bendamustine - also in breast cancer?
von Minckwitz G; Linder M; Loibl S
Onkologie; 2009 Sep; 32(8-9):462-3. PubMed ID: 19745588
[No Abstract] [Full Text] [Related]
20. Systemic treatment of melanoma: quo vadis oncologist?
Retsas S
J BUON; 2007; 12(1):29-32. PubMed ID: 17436398
[No Abstract] [Full Text] [Related]
[Next] [New Search]
